JPRN-UMIN000001630招募中4 期
A randomized clinical trial of an antiplatelet agent in the treatment of acute stroke: cilostazol in the prevention of acute progressing stroke (CAPS) study - CAPS study
Tohoku Acute Progressing Stroke Study Group0 个研究点目标入组 500 人开始时间: 2009年3月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) mRS before the onset > or = 2 2) NIHSS score > or = 20 3) Remarkably unstable symptom (measurement of NIHSS difficult) 4) Patients who should be treated with alteplase or other thrombolytic therapies 5) Patients who should be treated with reconstructive surgery (bypass or endovascular treatment) 6) Severe swallowing disturbance 7) Serious systemic complications (carcinoma,liver cirrhosis,renal failure, heart failure, etc.) 8) Contraindications to cilostazol 9) Patients who are considered unsuitable for inclusion in the study
研究者
相似试验
进行中（未招募）
1 期
The effect of antiplatelet therapy after angioplasty.EUCTR2016-002086-54-NLniversity Medical Center Utrecht1,806
尚未招募
不适用
A randomized trial of the effect of antiplatelet therapy (Aspirin, Aspirin and Clopidogrel or Ticagrelor) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty.antiplatelet therapy, peripheral transluminal angioplastyNL-OMON28759Antonius Hospital Nieuwegein, Medisch Centrum Alkmaar.1,252
已完成
4 期
A randomized trial of the effect of antiplatelet therapy (Aspirin, Aspirin and Clopidogrel or Ticagrelor) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty.peripheral arterial diseaseNL-OMON47750niversitair Medisch Centrum Utrecht1,806
进行中（未招募）
不适用
A pilot study investigating the antiplatelet effect of generic clopidogrel versus Plavix™ – is there any difference in platelet reactivity in healthy subjects? - The effect of Plavix versus generic clopidogrel on platelet reactivityThe intended indication for the product is for use in all patients with acute coronary syndromes and following coronary artery stentingEUCTR2010-022461-10-GBSouthampton University Hospitals NHS Trust15
进行中（未招募）
1 期
A study designed to evaluate a modified Anti-Platelet Therapy (drugs that prevent blood platelets from clotting) after implantation of a Firehawk drug-eluting stent (metallic tube, which is covered with a drug and inserted into stenosed blood vessels of the heart in order to keep them open) in patients who have experienced a heart attack and were treated with complete revascularisatioEUCTR2020-005933-34-NLSorin CRM SAS (Microport CRM)2,246